Beneficial effects of growth hormone replacement in growth hormone-deficient adults

Endocrinologist

Volumn 12, Issue 5, 2002, Pages 405-411

  Blevins, Lewis S ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; SOMATOMEDIN C;

BONE MINERAL; CARDIOVASCULAR RISK; FITNESS; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOTHALAMUS; INSULIN TOLERANCE TEST; IRRADIATION; MUSCLE MASS; MUSCLE STRENGTH; OBESITY; REVIEW; SELLA TURCICA TUMOR;

EID: 0036740436     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-200209000-00008     Document Type: Review

References (54)

1. Carrel AL, Allen DB: Effects of growth hormone on body composition and bone metabolism. Endocrine 2000; 12: 163-72.
2. Salomon F, Cuneo RC, Hesp R, et al.: The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: 1797-803.
3. Jorgensen JO, Pedersen SA, Thuesen L, et al.: Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989; 1: 1221-5.
4. Carroll PV, Christ ER, Bengtsson BA, et al.: Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998; 83: 382-95.
5. Alexander JK: Obesity and coronary heart disease. Am J Med Sci 2001; 321: 215-24.
6. Despres JP, Moorjani S, Lupien PJ, et al.: Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10: 497-511.
7. Rosen T, Bengtsson BA: Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-8.
8. Bates AS, Van't Hoff W, Jones PJ, et al.: The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996; 81: 1169-72.
9. Johansson AG, Engstrom BE, Ljunghall S, et al.: Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. J Clin Endocrinol Metab 1999; 84: 2002-7.
10. Cuneo RC, Judd S, Wallace JD, et al.: The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults. J Clin Endocrinol Metab 1998; 83: 107-16.
11. ter Maaten JC, de Boer H, Kamp O, et al.: Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J Clin Endocrinol Metab 1999; 84: 2373-80.
12. de Boer H, Blok GJ, Voerman B, et al.: Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men. Int J Obes Relat Metab Disord 1996; 20: 580-7.
13. Hew FL, O'Neal D, Kamarudin N, et al.: Growth hormone deficiency and cardiovascular risk. Baillieres Clin Endocrinol Metab 1998; 12: 199-216.
14. Johannsson G, Bengtsson BA: Growth hormone and the metabolic syndrome. J Endocrinol Invest 1999; 22: 41-6.
15. Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
16. Attanasio AF, Lamberts SW, Matranga AM, et al.: Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 1997; 82: 82-8.
17. Russell-Jones DL, Watts GF, Weissberger A, et al.: The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clin Endocrinol (Oxf) 1994; 41: 345-50.
18. Weaver JU, Monson JP, Noonan K, et al.: The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 1995; 80: 153-9.
19. Beshyah SA, Henderson A, Niththyananthan R, et al.: The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab 1995; 80: 356-63.
20. Wallymahmed ME, Foy P, Shaw D, et al.: Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years. Clin Endocrinol (Oxf) 1997; 47: 439-46.
21. Cuneo RC, Salomon F, Wiles CM, et al.: Growth hormone treatment in growth hormone-deficient adults. 11. Effects on exercise performance. J Appl Physiol 1991; 70: 695-700.
22. Merola B, Cittadini A, Colao A, et al.: Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 1993; 77: 1658-61.
23. Juul A, Behrenscheer A, Tims T, et al.: Impaired thermoregulation in adults with growth hormone deficiency during heat exposure and exercise. Clin Endocrinol (Oxf) 1993; 38: 237-44.
24. Jorgensen JO, Vahl N, Hansen TB, et al.: Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clin Endocrinol (Oxf) 1996; 45: 681-8.
25. Johannsson G, Grimby G, Sunnerhagen KS, et al.: Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab 1997; 82: 2877-84.
26. Janssen YJ, Doombos J, Roelfsema F: Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 1999; 84: 279-84.
27. Thuesen L, Jorgensen JO, Muller JR, et al.: Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults. Clin Endocrinol (Oxf) 1994; 41: 615-20.
28. Colao A, Di Somma C, Pivonello R, et al.: Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 1999; 84: 1919-24.
29. Johannsson G, Rosen T, Bosaeus I, et al.: Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1996; 81: 2865-73.
30. Bouillon R, Prodonova A: Growth and hormone deficiency and peak bone mass. J Pediatr Endocrinol Metab 2000; 13 Suppl 6: 1327-36.
31. Baum HB, Biller BM, Finkelstein JS, et al.: Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996; 125: 883-90.
32. Umland EM, Boyce EG: Risedronate: a new oral bisphosphonate. Clin Ther 2001; 23: 1409-21.
33. Sharpe M, Noble S, Spencer CM: Alendronate: an update of its use in osteoporosis. Drugs 2001; 61: 999-1039.
34. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996; 276: 1389-96.
35. Ohlsson C, Bengtsson BA, Isaksson OG, et al.: Growth hormone and bone. Endocr Rev 1998; 19: 55-79.
36. McGauley GA, Cuneo RC, Salomon F, et al.: Psychological well-being before and after growth hormone treatment in adults with growth hormone deficiency. Horm Res 1990; 33(S4): 52-4.
37. Bengtsson BA, Eden S, Lonn L, et al.: Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76: 309-17.
38. Burman P, Broman JE, Hetta J, et al.: Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab 1995; 80: 3585-90.
39. McKenna S, Doward L, Alonso J, et al.: The QoL-AGHDA: An instrument for the assessment of quality of life in adults with hormone deficiency. Pituitary Network Association. 2001.
40. American Association of Clinical Endocrinologists: AACE clinical practice guidelines for growth hormone use in adults and children. Endocrine Pract 1998; 4: 165-73.
41. Cook DM, Ludlam WH, Cook MB: The Adult Growth Hormone Deficiency Syndrome. In Advances in Internal Medicine, pp. 297-313. 2001.
42. Hartman ML, Crowe BJ, Chipman JJ, et al.: Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency (GHD). Abstract 2170. J Clin Endocrinol Metab 2002; 87: 477-85.
43. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998; 83: 379-81.
44. Valetto MR, Bellone J, Baffoni C, et al.: Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan. Eur J Endocrinol 1996; 135: 568-72.
45. Aimaretti G, Corneli G, Razzore P, et al.: Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab 1998; 83: 1615-8.
46. Burman P, Johansson AG, Siegbahn A, et al.: Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997; 82: 550-5.
47. Drake WM, Coyte D, Camacho-Hubner C, et al.: Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 1998; 83: 3913-9.
48. Allen DB: Safety of human growth hormone therapy: current topics. J Pediatr 1996; 128: S8-13.
49. Chan JM, Stampfer MJ, Giovannucci E, et al.: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-6.
50. Hankinson SE, Willett WC, Colditz GA, et al.: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393-6.
51. Jenkins PJ, Besser M: Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab 2001; 86: 2935-41.
52. Orme SM, McNally RJ, Cartwright RA, et al.: Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998; 83: 2730-4.
53. Marzullo P, Di Somma C, Pratt KL, et al.: Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab 2001; 86: 3001-8.
54. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001; 86: 1868-70.